Quality of life in patients with advanced gastroesophageal (GE) adenocarcinoma treated with modified docetaxel, cisplatin, and fluorouracil (mDCF)

被引：0
|
作者：
Smyth, E. C.
Janjigian, Y. Y.
Robinson, E.
Sheehy, E. C.
Karpenko, I.
Capanu, M.
Kelsen, D. P.
Shah, M. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group
    Ajani, Jaffer A.
    Moiseyenko, Vladimir M.
    Tjulandin, Sergei
    Majlis, Alejandro
    Constenla, Manuel
    Boni, Corrado
    Rodrigues, Adriano
    Fodor, Miguel
    Chao, Yee
    Voznyi, Edouard
    Marabotti, Cindy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3205 - 3209
  • [12] Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy (CRT).
    Driessen, Chantal
    Groenewoud, Hans
    De Boer, J. P.
    Gelderblom, Hans
    Tesselaar, Margot Et
    Van der Graaf, Winette T. A.
    Kaanders, J. H.
    L-Van Herpen, Carla M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [13] EFFICACY AND SAFETY OF TRIWEEKLY DOCETAXEL, OXALIPLATIN, FLUOROURACIL, AND FOLINIC ACID (DOFF) IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL ADENOCARCINOMA
    Ablavi, Adani-Ife
    Mazen, Haydar
    Pasquale, Innominato
    Ayhan, Ulusakarya
    Wathek, Al Mohamed
    David, Machover
    Emma, Goldschmidt
    Yusuf, Gumus
    Jean-Francois, Morere
    ANNALS OF ONCOLOGY, 2014, 25 : 37 - 37
  • [14] Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
    Fiteni, Frederic
    Paget-Bailly, Sophie
    Messager, Mathieu
    N'Guyen, Thierry
    Lakkis, Zaher
    Mathieu, Pierre
    Lamfichekh, Najib
    Picard, Alain
    Benzidane, Bilell
    Cleau, Denis
    Bonnetain, Franck
    Borg, Christophe
    Mariette, Christophe
    Kim, Stefano
    CANCER MEDICINE, 2016, 5 (11): : 3085 - 3093
  • [15] Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (dcf) compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma
    Kim, S.
    Paget-Bailly, S.
    Fiteni, F.
    Messager, M.
    Nguyen, T.
    Mathieu, P.
    Lamfichekh, N.
    Fein, F.
    Fratte, S.
    Cleau, D.
    Calcagno, F.
    Lakkis, Z.
    Jary, M.
    Sakek, N.
    Jacquin, M.
    Foubert, A.
    Bonnetain, F.
    Mariette, C.
    Borg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S449 - S450
  • [16] Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma
    Bayraktar, Ulas Darda
    Bayraktar, Soley
    Hosein, Peter
    Chen, Emerson
    Koniaris, Leonidas G.
    Rocha-Lima, Caio Max S.
    Montero, Alberto J.
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1707 - 1710
  • [17] Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma
    Ulas Darda Bayraktar
    Soley Bayraktar
    Peter Hosein
    Emerson Chen
    Leonidas G. Koniaris
    Caio Max S. Rocha-Lima
    Alberto J. Montero
    Medical Oncology, 2012, 29 : 1707 - 1710
  • [18] Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus
    Ui, T.
    Fujii, H.
    Hosoya, Y.
    Nagase, M.
    Mieno, M. N.
    Mori, M.
    Zuiki, T.
    Saito, S.
    Kurashina, K.
    Haruta, H.
    Matsumoto, S.
    Niki, T.
    Lefor, A.
    Yasuda, Y.
    DISEASES OF THE ESOPHAGUS, 2015, 28 (02) : 180 - 187
  • [19] Impact of first-line fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with advanced gastroesophageal adenocarcinoma: A retrospective analysis
    Lino, Aline Da Rocha
    Moreira, Raphael Brandao
    Gomes, Jessica Ribeiro
    Soares de Sousa, Tarcia Tarciane
    Abrahao, Carina Mina
    Martins Junior, Rodnei Merlrina
    Alessandretti, Matheus Bongers
    Fernandes Amarante, Marcus Paulo
    Barros Schutz, Fabio Augusto
    Kawamura, Carolina
    Schmerling, Rafael
    Cruz, Marcelo Rocha
    Maluf, Fernando C.
    Buzaid, Antonio C.
    Peixoto, Renata D'Alpino
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [20] Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial
    Goerling, Ute
    Gauler, Thomas
    Dietz, Andreas
    Gruenwald, Viktor
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Lindeman, Hans-Walter
    Fietkau, Rainer
    Haxel, Boris
    Grosse-Thie, Christina
    Maschmeyer, Georg
    Zipfel, Matthias
    Martus, Peter
    Knoedler, Maren
    Keilholz, Ulrich
    Klinghammer, Konrad
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 319 - 324
12345